ReviewNature reviews. Drug discovery2026
The expanding role of formulations to enable oral delivery of poorly water-soluble drugs.
Review in Nature reviews. Drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI-enabled engineering of hesperidin/ursodeoxycholic acid nanomedicine for synergistic treatment of drug-induced liver injury.Smart molecules : open access · 2026Article
- Enhanced Solubility of Famotidine through Salification.Crystal growth & design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contemporary small-molecule drug candidates increasingly have limited aqueous solubility, rendering oral delivery challenging. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) have evolved as leading formulation approaches to mitigate solubility and dissolution rate limitations. There is an increasing trend towards ASD formulations for drug candidates with high melting points and LBFs for extremely lipophilic molecules. Mechanistic assessment of LBF and ASD enhancement pathways reveals a surprising amount of commonality, notably that supersaturation generation and maintenance are likely key to obtaining optimized in vivo performance for both formulation types. An expanding formulation design space is blurring the distinction between these solubility enhancement technologies and further evolution in this direction is likely necessary to address the oral delivery of even more challenging molecules, such as proteolysis-targeting chimeras and macrocyclic peptides.
Indexed as
Identifiers
41927892What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.